Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (174)
ARTG (106)
Prescription medicine registration (26)
Australian public assessment report (AusPar) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)
Prescription medicine evaluation (1)

Date

2026 (4)
2025 (32)
2024 (120)
2023 (16)
2022 (13)
2021 (61)
2020 (23)
2019 (9)
2018 (5)
2017 (7)
2016 (18)
2015 (2)
2012 (1)
2011 (4)
2006 (3)
1995 (2)

Search

Sponsor content

320 result(s) found, displaying 211 to 220

AusPAR: Deutetrabenazine

27 May 2022

Australian public assessment report (AusPar)

AUSTEDO (deutetrabenazine) for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adult.
TE-RIVAROXABAN (Teva Pharma Australia Pty Ltd)

10 May 2022

Prescription medicine registration

Active ingredients: Rivaroxaban.
SITAGLIPTIN-TEVA, TE-SITAGLIPTIN, SITAGLIPTIN-TV (Teva Pharma Australia Pty Ltd)

14 February 2022

Prescription medicine registration

Active ingredients: sitagliptin malate.
AJOVY fremanezumab 225 mg/1.5 mL solution for injection in a pre-filled syringe (308630)

20 September 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for AJOVY fremanezumab 225 mg/1.5 mL solution for injection in a pre-filled syringe.
AZACITIDINE-TEVA azacitidine 100 mg powder for injection vial (299040)

23 July 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for AZACITIDINE-TEVA azacitidine 100 mg powder for injection vial.
Notice for edaravone (Teva Pharma Australia Pty Ltd)

17 August 2021

Designation or determination

Orphan drug
DEFERASIROX-TEVA, TE-DEFERASIROX (Teva Pharma Australia Pty Ltd)

6 August 2021

Prescription medicine registration

Active ingredients: deferasirox.
TEVATREXED pemetrexed (as disodium) 500mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TEVATREXED pemetrexed (as disodium) 100mg powder for injection vial Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
DONEPEZIL-TEVA donepezil hydrochloride (as monohydrate)10 mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2021

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd

Pages

First page
Previous page
…
Page 18
Page 19
Page 20
Page 21
Current page 22
Page 23
Page 24
Page 25
Page 26
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.